Sexually transmitted diseases - An update

Harefuah

Volumn 144, Issue 4, 2005, Pages 272-278

  Davidovitch, Nadav ^a   Shohat, Tami ^b   Dan, Michael ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Epidemiology; Prevention; Public health; Sexually Transmitted Diseases (STD); Treatment

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ISRAEL; NEISSERIA GONORRHOEAE; PUBLIC HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; FEMALE; HUMAN; INCIDENCE; MALE; PATIENT CARE; URBAN POPULATION;

FEMALE; HUMANS; INCIDENCE; ISRAEL; MALE; PATIENT CARE TEAM; SEXUALLY TRANSMITTED DISEASES; URBAN POPULATION;

EID: 21244491079     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. World Health Organiztion Regional Office for Europe. Centralized Information system for infectious diseases (CISID); sexually transmitted infections, http://data.euro.who.int/cisid
2. Green M, Anis E, Gandacu D & Grotto I, The fall and rise of gonorrhoea incidence in Israel: an international phenomenon? Sex Transm Infect, 2003; 79: 116-118.
3. Dan M, Poch F & Sheinberg B, High prevalence of high-level ciprofloxacin resistance in Neisseria gonorrhoeae in central Israel: correlation with response to therapy. Antimicrob Agents Chemother, 2002; 46: 1671-1673.
4. Samra Z, Scherf E & Dan M, Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel. Sex Trans Dis, 2003; 30: 794-796.
5. Israel Center for Disease Control. Notifiable Infectious Diseases in Israel. 50 Years of surveillance, 1951-2001. Ministry of Health, State of Israel. Publication No 224, July 2003.
6. Gerbase AC, Global prevalence and incidence estimates of selected curable STDs. Sex Trans Infect, 1998; 74(suppl 1): S12-S13.
7. Dan M, Sexually Transmitted Diseases. In: Kanishkowy B, Amitay Y & Honovitch M, (Eds.), School Health - Practical Information. Jerusalem, Ministry of Health, Public Health Services, 2003: 288-294.
8. Rottingen J-A, Cameron WD & Garnett GP, A systematic review of the epidemiologic interaction between classic sexually transmitted diseases and HIV. How much really is known? Sex Transm Dis, 2001; 28: 579-592
9. th European Congress of Chemotherapy and Infection, Rhodes, Greece, October 2003.
10. Bamberger ES, Siegler E, Makler- Shiran E & al, Chlamydia trachomatis infections in female soldiers, Israel. Emerg Infect Dis, 2003; 10: 1344-1346.
11. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Surveillance, 2003. Atlanta, GA: U.S. Department of Health and Human Services, September 2004.
12. Yagupsky P, Schahar A, Peled N & al, Increasing incidence of gonorrhea in Israel associated with countrywide: Dissemination of a ciprofloxacin resistant strain. Eur J Clin Microbiol Infect Dis, 2002; 21: 268-72.
13. Dan M. The use of fluoroquinolones in gonorrhea: The increasing problem of resistance. Expert Opin Pharmacother 2004; 5: 829-854.
14. Annual Report of the Australian Gonococcal Surveillance Programme, 2000. Commun Dis Intell, 2001; 25: 59-63.
15. Berglund T, Unemo M, Olcen P, Giesecke J & Fredlund H. One year of Neisseria gonorrhoeae isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. Int J STD AIDS, 2002; 13: 109-114.
16. Johnson RE, Newhall WJ, Papp JR, & al, Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections - 2002. MMWR Recomm Rep, 2002; 51(RR-15): 1-38.
17. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 200. MMWR 2002; 51(No. RR-6): 1-81.
18. Peipert JF, Genital chlamydial infections. N Engl J Med, 2003; 349: 2424-2430.
19. Gotz H, Lindback J, Ripa T & al, Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods? Scand J Infect Dis, 2002; 34: 28-34.
20. Sompolinsky D, Harari Z, Solomon F & al, A contribution to the microbiology of urethritis. Isr J Med Sci, 1973; 9: 438-46.
21. Hagay ZJ, Sarov B, Sachs J & al, Detecting Chlamydia trachomatis in men with urethritis: serology vs isolation in cell culture. Genitourin Med, 1989; 65: 166-70.
22. Herman A, Roash Z, Samra Z & al, Prevalence of low genital tract infectious agents in young Israeli women. Isr J Med Sci, 1985; 21: 346-50.
23. Samra Z, Dan M, Segev S & al, Prevalence of sexually transmitted pathogens among women attending a methadone clinic in Israel. Genitourin Med, 1991; 67: 133-136.
24. Dan M, Kaneti N, Levin D & al, Vaginitis in a gynecological practice in Israel: causes and risk factors. Isr Med Assoc J, 2003; 5: 629-632.
25. Srugo I, Steinberg J, Madeb R & al, Agents of non-gonococcal urethritis in males attending an Israeli clinic for sexually transmitted diseases. Isr Med Assoc J, 2003; 5: 24-27.
26. Samra Z, Rosenberg S, Soffer Y & Dan M, In-vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis, 2001; 39: 177-179.
27. Martin DH, Mrocxkowski TF, Dalu AZ & al, A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med, 1992; 327: 921-925.
28. Taylor-Robinson D & Horner PJ, The role of Mycoplasma genitalium in non-gonococcal urethritis. Sex Transm Infect, 2001; 77: 229-231.
29. Schwebke JR & Hook III EW, High rates of Trichomonas vaginalis among men attending a sexually diseases clinic: implication of screening and urethritis management. J Infect Dis, 2003; 188: 465-468.
30. Sobel J, Nagappan F & Nyirjesy P, Mertonidazole-resistant vaginal trichomoniasis - an emerging problem. N Engl J Med, 1999; 341: 292-293.
31. Isacsohn M, Smetana Z, Rones ZZ & al, A sero-epidemiological study of herpes simplex virus type 1 and 2 infection in Israel. J Clin Virol, 2002; 24: 85-92.
32. Dan M, Sadan O, Glezarman M & al, Prevalence and risk factors for herpes simplex virus type 2 infection among pregnant women in Israel. Sex Transm Dis, 2003; 30: 835-838.
33. Feldman PA, Steinberg J, Madeb R & al, Herpes simplex virus type 2 seropositivity in a sexually transmitted disease clinic in Israel. IMAJ, 2003; 5: 626-628.
34. Samra Z, Scherf E & Dan M, Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel. Sex Transm Dis 2003; 30: 794-796
35. Kimberlin DW & Rouse DJ, Genital herpes. N Engl J Med 2004; 350: 1970-1977.
36. Wald A, Carrell D, Remington M & al, Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis, 2002; 34: 944-948.
37. Leone P, Trottier S & Miller JM, Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis, 2002; 34: 958-962.
38. Stanberry LR, Spruance SL, Cunningham AL & al, Glycoprotein-D- adjuvant vaccine to prevent genital herpes. N Engl J Med, 2002; 347: 1652-1661.
39. Koutsky LA, Ault KA, Wheeler CM, & al, A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 2002; 347: 1645-1651.